Page last updated: 2024-12-06
cimetidine sulfoxide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
cimetidine sulfoxide: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 62949 |
| CHEMBL ID | 3544520 |
| CHEBI ID | 30731 |
| SCHEMBL ID | 7192902 |
| SCHEMBL ID | 11179015 |
| MeSH ID | M0105185 |
Synonyms (33)
| Synonym |
|---|
| 2-cyano-1-methyl-3-(2-{[(5-methyl-1h-imidazol-4-yl)methyl]sulfinyl}ethyl)guanidine |
| CHEBI:30731 , |
| cimetidine sulfoxide |
| cimetidine s-oxide |
| 54237-72-8 |
| 1-cyano-2-methyl-3-[2-[(5-methyl-1h-imidazol-4-yl)methylsulfinyl]ethyl]guanidine |
| h6v3t9ug74 , |
| unii-h6v3t9ug74 |
| guanidine, n-cyano-n'-methyl-n''-(2-(((5-methyl-1h-imidazol-4-yl)methyl)sulfinyl)ethyl)- |
| n-cyano-n'-methyl-n-[2-((4-methyl-5-imidazolyl)methyl sulphinyl)ethyl]guanidine |
| HOJLJLYVNQFCRE-UHFFFAOYSA-N |
| SCHEMBL7192902 |
| SCHEMBL11179015 |
| skf-92452 |
| (+/-)-cimetidine s-oxide |
| cimetidine sulfoxide, (+/-)- |
| guanidine, n-cyano-n'-methyl-n''-(2-(((4-methyl-1h-imidazol-5-yl)methyl)sulfinyl)ethyl)- |
| unii-e1296x9v0x |
| unii-6ve31s69b1 |
| CHEMBL3544520 |
| 2-cyano-1-methyl-3-[2-[[(5-methyl-1h-imidazol-4-yl)methyl]sulphinyl]ethyl]guanidine (cimetidine sulphoxide) |
| Q27113965 |
| cimetidine sulphoxide dihydrochloride |
| n-cyano-n''-methyl-n'-{2-[(4-methyl-1h-imidazol-5-yl)methanesulfinyl]ethyl}guanidine |
| DTXSID50969219 |
| BS-52765 |
| 1-cyano-3-methyl-2-(2-(((4-methyl-1h-imidazol-5-yl)methyl)sulfinyl)ethyl)guanidine |
| CS-0128291 |
| HY-136338 |
| n-cyano-n''-methyl-n'-{2-[(5-methyl-1h-imidazol-4-yl)methanesulfinyl]ethyl}guanidine |
| 2-cyano-1-methyl-3-[2-(5-methylimidazol-4-ylmethylsulphinyl)ethyl]guanidine |
| F77372 |
| AKOS040756206 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| "21 l/h per kg) with a consequent increase in half-life (24." | ( Dose-dependent pharmacokinetics of cimetidine in the rat. Aarons, L; Adedoyin, A; Houston, JB, 1987) | 0.27 |
| " time data were analysed by non-linear least squares regression analysis to determine pharmacokinetic parameter estimates." | ( Pharmacokinetics of intravenous and intragastric cimetidine in horses. I. Effects of intravenous cimetidine on pharmacokinetics of intravenous phenylbutazone. Ashcraft, SM; Dyke, TM; Gerken, DF; Reed, SM; Sams, RA, 1997) | 0.3 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " The proposed method is rapid, accurate and precise, and it should be useful for clinical, bioavailability and pharmacokinetic studies of cimetidine." | ( An improved high performance liquid chromatographic method for determination of cimetidine and its major metabolite in plasma. Cervantes-Campos, C; Delgadillo-Valencia, MP; Girard-Cuesy, ME; León-Urrea, F; Montoya-Cabrera, MA, ) | 0.13 |
| " The median (range) extent of intragastric bioavailability was 14." | ( Pharmacokinetics of intravenous and intragastric cimetidine in horses. I. Effects of intravenous cimetidine on pharmacokinetics of intravenous phenylbutazone. Ashcraft, SM; Dyke, TM; Gerken, DF; Reed, SM; Sams, RA, 1997) | 0.3 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " This same dosage in obese individuals with normal serum creatinine values should result in the same average steady-state serum concentrations." | ( Cimetidine clearance in the obese. Bauer, LA; Dellinger, EP; Edwards, WA; Ferreri, L; Jack, R; Raisys, V; Simonowitz, D; Wareing-Tran, C, 1985) | 0.27 |
| " Because of the 40% decrease in total clearance, dosage in cirrhotic patients with a history of PSE should be reduced to minimize the risk of CNS side effects associated with cimetidine." | ( Hepatic encephalopathy and altered cimetidine kinetics. Bernhard, H; Schentag, JJ; Ziemniak, JA, 1983) | 0.27 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| sulfoxide | An organosulfur compound having the structure R2S=O or R2C=S=O (R =/= H). |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (10)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (60.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.58
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.58) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||